Provenge - malecare.org

Dendreon Has Three Posters At ASCO That Add New And Great News For Men With Advanced Prostate Cancer

The American Society of Clinical Oncologists (ASCO) posted on Wednesday the abstracts from the Genitourinary Conference which is scheduled for February 2-4 in San Francisco, California. Dendreon, the creator of the immunotherapy Provenge for men with metastatic castrate resistant advanced prostate cancer has three very interesting and informative posters which will appear at the conference. [...]

By Malecare|2021-02-17T11:03:31-05:00February 3rd, 2012|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, Provenge, Research, Uncategorized, vaccines|0 Comments

A Look at the Status of Cancer Vaccines – Emerging Treatments

From very early on, researchers and doctors have dreamed of using the body’s own immune system to fight cancer. The big question has been why doesn’t the immune system attack the tumor cells that invade healthy tissue? The really good news is that finally science is catching up with this vision. Therapeutic cancer vaccines that [...]

By Malecare|2011-12-20T14:34:32-05:00December 20th, 2011|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, ipilimumab, Prostvac, Provenge, Research, Uncategorized, Understanding APC, vaccines, Yervoy|1 Comment

On The Horizon – Some More Information & An Update On MDV3100

Many of us are aware of the newly approved drug Zytiga (abiraterone). It had demonstrated a survival advantage for men who are castrate resistant and failed chemotherapy. Zytiga was approved by the FDA in April and many of us with advanced prostate cancer have been taking advantage of the drug. You can learn more about [...]

By Malecare|2017-10-19T10:51:59-04:00October 16th, 2011|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, MDV3100, On The Horizon, Provenge, Uncategorized, Understanding APC|2 Comments

Provenge Receives A Positive National Determination from CMS

Yesterday Dendreon, the producers of Provenge, received word from the FDA that their plant in California had been approved to manufacture Provenge. This afternoon they received a positive response from the Centers for Medicare and Medicaid Services (CMS) that a final National Coverage Decision (NCD) for Provenge has been issued requiring Medicare contractors to cover [...]

By Malecare|2017-10-19T10:52:21-04:00June 30th, 2011|Advanced Prostate Cancer, Drugs & Treatments, Financial, General Information, Insurance, Politics of Cancer, Provenge, Uncategorized|6 Comments

Dendreon Receives Approval for Their New Plant in California

Early this evening Dendreon received the nod from the FDA to use their new manufacturing plant in Seal Beach, California. The approval of this plant will allow the company to now service the men with advanced prostate cancer in Hawaii as well as more efficiently service those in Western United States with Provenge. When coupling [...]

By Malecare|2011-06-29T22:04:37-04:00June 29th, 2011|Advanced Prostate Cancer, Drugs & Treatments, Provenge, Uncategorized, vaccines|0 Comments